A pharmaceutical licensing agreement is the primary mechanism by which drug candidates move from early-stage developers, often academic spinouts or small biotechs, to larger development and commercialization partners. The terms of a pharma licensing agreement determine how much value the licensor realizes from years of research investment. Getting these terms right requires understanding both the legal structure and the industry conventions for pricing, milestone structures, and diligence obligations. At Lopes Law LLC, we advise small biotech and pharma clients on licensing agreement structure and negotiation strategy.

What Are the Core Components of a Pharmaceutical License Agreement?

The licensed technology or IP defines exactly what is being licensed: a specific compound or compound family, a patent family (which claims must be specified), a formulation, a manufacturing process, or a data package from clinical studies. Vague definitions create disputes about scope later. The license must be precisely defined from the first drafting session.

The license scope has three dimensions: exclusivity (exclusive, co-exclusive, or non-exclusive), territory (worldwide, specific countries, or specific regions), and field of use (a specific therapeutic indication, all oncology indications, or all uses). A narrowly scoped license may allow the licensor to retain valuable rights while granting the partner what they actually need. A broad scope may create higher upfront payments but forecloses future optionality.

The upfront license fee is paid at signing. It is non-refundable and compensates the licensor for the value transferred regardless of subsequent development success. Upfront fees range from a few hundred thousand dollars for pre-clinical assets to tens of millions for late-stage or approved products. Negotiating a meaningful upfront payment is important because development milestones may be years away and are contingent on success.

Another critical element is the term of the license. Most pharma licenses run for the life of the patent or the last-to-expire patent in the licensed patent family, plus a post-patent royalty term at a reduced rate. The post-patent royalty term typically runs 5 to 10 years after patent expiry at a rate reduced by 30 to 50%. At Lopes Law LLC, we advise small biotech licensors to negotiate specific post-patent terms at the outset, because generic competition after patent expiry significantly reduces net sales and the royalty base.

How Are Royalty Rates Structured in Pharma Licensing?

Royalty rates in pharmaceutical licensing are typically expressed as a percentage of net sales and vary significantly based on the development stage of the licensed asset at the time of the deal. Industry benchmarks from Lopes Law LLC experience and published comparable transactions: pre-clinical assets typically 2 to 5% of net sales; Phase 1 assets 3 to 8%; Phase 2 assets 5 to 10%; Phase 3 assets 8 to 15%; approved products 10 to 20%.

The net sales definition is as important as the headline royalty rate because it determines the actual royalty base. Permitted deductions from gross sales to arrive at net sales typically include: sales taxes, government-mandated price adjustments, Medicaid and Medicare rebates, managed care chargebacks, returns, and freight. Licensees often push for broad deduction lists that can significantly reduce the royalty base, particularly in markets with substantial government price controls.

Royalty stacking provisions address the situation where the licensee must pay royalties to multiple third parties for IP needed to commercialize the licensed product. Stacking provisions allow the licensee to reduce the royalty paid to the licensor when total royalty obligations to all parties exceed a threshold. At Lopes Law LLC, we negotiate royalty stacking floors (minimum royalty regardless of stacking) and caps on the stacking reduction to protect the licensor’s economic interest.

What Milestone Payment Structures Work Best for Small Biotech?

Development milestones are payments triggered by achieving specific regulatory or clinical events. Industry benchmarks: IND filing or acceptance (1 to 5 million dollars), Phase 1 completion or proof of concept (5 to 20 million dollars), Phase 2 completion (10 to 50 million dollars), NDA or BLA filing (20 to 100 million dollars), regulatory approval (50 to 250 million dollars), EU approval (10 to 50 million dollars depending on territory scope).

Commercial milestones are triggered by achieving specific net sales thresholds. First year achieving 100 million dollars in net sales might trigger a payment of 10 to 50 million dollars; 500 million dollars in net sales might trigger 25 to 100 million dollars. Commercial milestones reward blockbuster performance without requiring the licensor to wait for royalty accumulation over time.

Milestone stacking provisions address what happens if a development milestone is skipped. For example, if the drug receives breakthrough therapy designation and moves directly from Phase 2 to Phase 3 without a traditional Phase 2 completion event, is the Phase 2 milestone paid? The agreement should specify that milestones are paid upon the first occurrence of the triggering event regardless of whether earlier milestones were skipped.

Timing of milestone payments also matters from a cash flow perspective. Some licensees push for payment within 60 to 90 days of a milestone event. The licensor should negotiate for payment within 30 days and include interest provisions for late payments, typically at the lower of the prime rate plus 2% or the maximum rate permitted by law. For a small biotech relying on milestone payments to fund ongoing research, even a 30-day delay in a 20 million dollar milestone payment has meaningful financial consequences. At Lopes Law LLC, we build specific payment timing and interest provisions into every milestone schedule we negotiate.

Anti-shelving protections are closely related to milestones. If the licensee acquires a competing compound after signing the license agreement and decides to prioritize the competing compound over the licensed asset, milestone payments may never be triggered. The licensor should negotiate for a specific anti-shelving clause that triggers reversion of rights if the licensee begins developing a directly competing compound within the same therapeutic indication. Without this protection, the licensor’s most valuable asset can be effectively removed from the market by a competitor that licensed it specifically to suppress it.

What Diligence Obligations Protect the Licensor?

The licensee’s diligence obligations are among the most important provisions in a pharma license agreement for the licensor’s long-term protection. Without strong diligence obligations, the licensee can accept the license, pay the upfront fee, and then deprioritize development indefinitely while the licensor receives no milestone payments and cannot license to anyone else.

The standard “commercially reasonable efforts” diligence standard is commonly used but is very difficult to enforce in litigation because of its inherent vagueness. More protective structures include: specific minimum annual development spend obligations (with the right to terminate the license and recover all rights if not met), specific milestone deadlines with reversion consequences for missing them, and specific commercialization obligations after approval (minimum promotional spend, minimum sales force dedication). At Lopes Law LLC, we always push for defined, measurable diligence requirements rather than relying on the commercially reasonable efforts standard alone.

Consider a small biotech that licensed its Phase 2 compound to a large pharma for 5 million dollars upfront, with 200 million dollars in potential milestones. Two years later, the large pharma’s internal pipeline shifted priorities and the licensed compound was deprioritized. Under commercially reasonable efforts language without further specifics, the large pharma argued they were still exercising commercially reasonable efforts by keeping the program in their pipeline while not actively advancing it. The licensor had no meaningful recourse. With specific development milestone deadlines and reversion rights, the licensor could have reclaimed the compound and relicensed it to another partner.

What Sublicensing Rights Should the Licensor Negotiate?

If the licensee may sublicense to third parties, the licensor should negotiate a meaningful share of sublicensing revenues. Industry standard sublicensing revenue sharing for pre-clinical assets ranges from 20 to 40% of sublicensing consideration paid to the licensee. For more advanced assets, the share may be lower because the licensee has added more development value.

Sublicensing provisions should also address: notification requirements (the licensor should know when sublicenses are granted), sublicensee obligations (the sublicensee should be bound by diligence obligations at least as protective as the licensee’s), and survival on termination (if the main license is terminated, existing sublicenses from a sublicensee with ongoing development programs may need to survive under certain conditions).

One area often overlooked in sublicensing negotiations is the distinction between sublicensing revenue and milestone payments. When a licensee sublicenses to a regional partner, the sublicensing consideration may include an upfront payment, milestone payments, and royalties. The licensor’s share of sublicensing revenue should apply to all three categories. Some agreements only require revenue sharing on the upfront payment, allowing the licensee to retain 100% of sublicensee milestones and royalties. At Lopes Law LLC, we draft sublicensing provisions that capture the full economic value of any downstream partnership.

Sublicensing audit rights are another critical protection. The licensor should retain the right to audit sublicensee records, not just the licensee’s records, to verify that royalty calculations are accurate. Without this right, the licensor depends entirely on the licensee’s reporting of sublicensee sales, with no independent verification mechanism. Industry standard audit provisions allow one audit per year at the licensor’s expense, with the licensee bearing the cost if an underpayment exceeding 5% is discovered.

How Does Lopes Law LLC Help With Pharma Licensing Agreements?

At Lopes Law LLC, Anthony Lopes, Esq. brings a unique combination of BigLaw transactional experience from Duane Morris LLP and hands-on pharmaceutical industry experience from Merck’s clinical trials launch department through CRO PRA Pharmaceuticals. This means we understand both the legal structure of licensing agreements and the practical realities of how these deals play out over a 10 to 15 year drug development timeline.

We advise small biotech and pharma clients on: structuring upfront and milestone payment schedules that reflect the asset’s development stage, benchmarking royalty rates against comparable transactions in the same therapeutic area, drafting diligence obligations with specific milestones and reversion consequences, negotiating sublicensing terms that protect the licensor’s long-term economic interest, and reviewing net sales definitions to prevent excessive deductions from the royalty base. Our flat fee structure means clients know their costs upfront before the engagement begins.

For pre-clinical and Phase 1 stage companies, the licensing agreement may be the single largest transaction the company will ever enter. Getting the structure right at the outset determines how much value the founders and investors realize from years of research. A licensing agreement review with Lopes Law LLC typically takes 2 to 3 weeks and includes a written analysis of the key commercial and legal terms, a comparison to industry benchmarks, and specific negotiating recommendations. For companies with active investor discussions, having a well-structured licensing agreement also strengthens the company’s valuation narrative by demonstrating that milestone economics and reversion protections are in place.

Reach out, we are friendly. Call now for a free consultation at (267) 777-9117.

This article is for informational purposes only and does not constitute legal advice. Consult a licensed attorney before making any legal decisions.

Related reading: Pharmaceutical NDAs | International Pharma Agreements | Pharma Confidentiality Agreements